Add this topic to your myFT Digest for news straight to your inbox
Japanese drugmaker is looking to reduce its $48bn debt following Shire acquisition
Japanese pharmaceutical group eyes reduction in $48bn debt pile following acquisition
If gene therapy lives up to its promise, it will justify the song and dance
Vote paves way for Japan’s largest ever corporate takeover
Takeda could be just the first of many looking for growth through acquisitions abroad
Former chair and member of founding family of Japanese drugmaker opposes acquisition
Unhappy shareholders are right to resist the purchase of Shire
Bankers, lawyers and PR advisers to receive huge payday for Japan’s largest overseas takeover
Closely watched meeting comes as some shareholders step up campaign to derail deal
Fears over sales of Velcade support case for £46bn deal to buy Shire
Chip deal that appeared to offer easy winnings caught in US-China tensions
Japanese drugmaker awaits antitrust decisions in Japan, Europe and China
Investor group had sought to derail Japanese drugmaker’s £46bn takeover of Shire
Christophe Weber ‘very comfortable’ with durability of lucrative haemophilia franchise
Their outlook may be traditional but that does not mean shareholders are wrong
Hokugo to stress dangers of cross-holdings and ‘allegiants’ hidden in registers
Dissident group has little actual clout but carries influence of founding family members
Christophe Weber says focus on orphan drugs will help combined group in ‘tougher’ environment
Pharma group backs offer from Japanese rival after rejecting four previous bids
The seven stages of grief when an asset management contract is terminated
International Edition